Your browser doesn't support javascript.
loading
Cancer is not a risk factor for severe COVID-19 in children, except in patients with recent allogeneic hematopoietic stem cell transplantation or comorbidities.
Velasco Puyó, Pablo; Tagarro, Alfredo; Garcia-Obregon, Susana; Villate, Olatz; Moraleda, Cinta; Huerta Aragonés, Jorge; Bardón Cancho, Eduardo J; Faura Morros, Anna; Galán-Gómez, Víctor; Escobar Fernández, Laura; Lendinez-Molinos, Francisco; Herrero Velasco, Blanca; Ureña Horno, Laura; Domínguez-Pinilla, Nerea; Pascual Gazquez, Juan Francisco; Nova Lozano, Cristina; Osuna-Marco, Marta; Marín-Cruz, Inés; Gomez Pastrana, Irene; Garcia de Andoin Barandiaran, Nagore; Gallego Mingo, Nerea; Portugal Rodríguez, Raquel; Cañete, Adela; Pareja León, Marta; Castrillo Bustamante, Sara; Tallón García, María; Gónzalez-Prieto, Almudena; Solé-Rodríguez, María; González Cruz, Macarena; Soriano-Arandes, Antonio; Mota, Miriam; Pérez-Hoyos, Santiago; Moreno, Lucas; Astigarraga, Itziar.
Afiliación
  • Velasco Puyó P; Pediatric Oncology and Hematology Department, Vall d'Hebron Barcelona Hospital, Barcelona, Spain.
  • Tagarro A; Fundación de Investigación Biomédica Hospital 12 de Octubre, Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain.
  • Garcia-Obregon S; Department of Pediatrics, Infanta Sofía University Hospital, Fundación para la Investigación Biomédica e Innovación Hospital Universitario Infanta Sofía y Hospital del Henares (FIIB HUIS HHEN), Madrid, Spain.
  • Villate O; Universidad Europea de Madrid, Madrid, Spain.
  • Moraleda C; BioBizkaia Health Research Institute, Pediatric Oncology Group, Barakaldo, Spain.
  • Huerta Aragonés J; UPV/EHU, Physiology Department, Universidad del País Vasco/Euskal Herriko Unibertsitatea, Leioa, Spain.
  • Bardón Cancho EJ; BioBizkaia Health Research Institute, Pediatric Oncology Group, Barakaldo, Spain.
  • Faura Morros A; Fundación de Investigación Biomédica Hospital 12 de Octubre, Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain.
  • Galán-Gómez V; Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Escobar Fernández L; Paediatrics Department, Paediatric and Adolescent Haematology and Oncology Section, Hospital Materno-Infantil del Complejo Hospitalario General Universitario Gregorio Marañón, Madrid, Spain.
  • Lendinez-Molinos F; Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
  • Herrero Velasco B; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Ureña Horno L; Paediatrics Department, Paediatric and Adolescent Haematology and Oncology Section, Hospital Materno-Infantil del Complejo Hospitalario General Universitario Gregorio Marañón, Madrid, Spain.
  • Domínguez-Pinilla N; Faculty of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
  • Pascual Gazquez JF; Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Nova Lozano C; Pediatric Oncology and Hematology Unit, Hospital Sant Joan de Déu, Barcelona, Spain.
  • Osuna-Marco M; Pediatric Oncology and Hematology Department, Hospital Infantil Universitario La Paz, Madrid, Spain.
  • Marín-Cruz I; Pediatric Oncology and Hematology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Gomez Pastrana I; Pediatric Oncology and Hematology Department, Hospital Infantil Infanta Leonor, Almería, Spain.
  • Garcia de Andoin Barandiaran N; Pediatric Oncology and Hematology Unit, Hospital Infantil Universitario del Niño Jesús, Madrid, Spain.
  • Gallego Mingo N; Hospital Doctor Balmis de Alicante, Alicante, Spain.
  • Portugal Rodríguez R; Pediatric Oncology Unit, Complejo Hospitalario de Toledo, Toledo, Spain.
  • Cañete A; i+12 Research Institute, Hospital 12 de Octubre, Madrid, Spain.
  • Pareja León M; Pediatric Oncology and Hematology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Castrillo Bustamante S; Hospital Clínico Universitario Valencia, Valencia, Spain.
  • Tallón García M; Pediatric Oncology and Hematology Unit, HM Hospitals, Madrid, Spain.
  • Gónzalez-Prieto A; Paediatric Infectious Diseases, Rheumatology and Immunology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Solé-Rodríguez M; Congenital Alterations of Immunity Group, Infectious Diseases and Immune System Area, Instituto de Biomedicina de Sevilla, Sevilla, Spain.
  • González Cruz M; Pediatric Infectious Disease Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Soriano-Arandes A; Pediatric Oncology and Hematology Unit, Donostia University Hospital, San Sebastián, Spain.
  • Mota M; Biogipuzkoa Health Research Institute, Pediatric Group, Paseo Dr. Begiristain, San Sebastián, Spain.
  • Pérez-Hoyos S; UPV/EHU, Pediatric Department, Paseo Dr. J. Beguiristain, Universidad del País Vasco/Euskal Herriko Unibertsitatea, San Sebastian, Spain.
  • Moreno L; Paediatrics Department, Hospital Universitario Son Espases, Mallorca, Spain.
  • Astigarraga I; Pediatric Oncology and Hematology Department, Hospital Universitario de Burgos, Burgos, Spain.
Pediatr Blood Cancer ; 71(8): e31120, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38825724
ABSTRACT
The EPICO (Spanish general registry of COVID-19 in children)-SEHOP (Spanish Society of Pediatric Hematology and Oncology) platform gathers data from children with SARS-CoV-2 in Spain, allowing comparison between children with cancer or allogeneic hematopoietic stem cell transplantation (alloHSCT) and those without. The infection is milder in the cancer/alloHSCT group than in children without comorbidities (7.1% vs. 14.7%), except in children with recent alloHSCT (less than 300 days), of which 35.7% experienced severe COVID-19. These data have been shared with the SEHOP members to support treatment and isolation policies akin to those for children without cancer, except for those with recent alloHSCT or additional comorbidities. This highlights the collaborative registries potential in managing pandemic emergencies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Comorbilidad / Trasplante de Células Madre Hematopoyéticas / SARS-CoV-2 / COVID-19 / Neoplasias Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Comorbilidad / Trasplante de Células Madre Hematopoyéticas / SARS-CoV-2 / COVID-19 / Neoplasias Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Pediatr Blood Cancer Asunto de la revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: España